Larry Herrera
Impact in
- Hematology top 10%
- Chronic Myeloid Leukemia Treatments
-
- CAR-T cell therapy research
- Neutropenia and Cancer Infections
Papers in
-
- Cancer therapeutics and mechanisms 4
-
- Toxin Mechanisms and Immunotoxins 5
- Co-authors
- Eric Sandler (4 shared papers)Ellen S. Vitetta (3 shared papers)Roula Farah (2 shared papers)George R. Buchanan (3 shared papers)Victor Gheţie (4 shared papers)Deborah B. Aquino (2 shared papers)Victor M. Aquino (2 shared papers)Birgitta Clinchy (1 shared paper)
- Journals
- Cancer (2 papers)Leukemia (2 papers)Cancer Research (2 papers)Journal of Clinical Oncology (1 paper)Critical Reviews in Eukaryotic Gene Expression (1 paper)
- Partner nations
- United StatesPolandCanada
In The Last Decade
Larry Herrera
13 papers receiving 392 citations
Peers
Comparison fields: 5 of 59
- Hematology 85
- Oncology 167
- Immunology 125
- Biotechnology 51
- Genetics 58
Countries citing papers authored by Larry Herrera
This map shows the geographic impact of Larry Herrera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Larry Herrera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Larry Herrera more than expected).
Fields of papers citing papers by Larry Herrera
This network shows the impact of papers produced by Larry Herrera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Larry Herrera. The network helps show where Larry Herrera may publish in the future.
Co-authors
The 25 scholars most cited alongside Larry Herrera, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2009 | 73 | |
| 2 | 2008 | 65 | |
| 3 | 1998 | 61 | |
| 4 | 2000 | 60 | |
| 5 | 2000 | 57 | |
| 6 | 2003 | 39 | |
| 7 | 2007 | 17 | |
| 8 | 2000 | 15 | |
| 9 | 2006 | 13 | |
| 10 | 2000 | 11 | |
| 11 | The anti-CD19 immunotoxin (HD37-dgRTA) is more effective when combined with chemotherapy | 2005 | 2 |
| 12 | 2016 | 1 | |
| 13 | 2000 | 1 |
About Larry Herrera
Larry Herrera is a scholar working on Molecular Biology, Immunology, Neurology, Oncology and Public Health, Environmental and Occupational Health, having authored 13 papers that have together received 415 indexed citations. Recurring topics across this work include Toxin Mechanisms and Immunotoxins (5 papers), Cancer therapeutics and mechanisms (4 papers), Acute Lymphoblastic Leukemia research (3 papers), Neuroblastoma Research and Treatments (3 papers), Blood disorders and treatments (2 papers), Chronic Lymphocytic Leukemia Research (2 papers), Monoclonal and Polyclonal Antibodies Research (2 papers) and Neutropenia and Cancer Infections (2 papers). The work is most often cited by research in Hematology (85 citations), Oncology (167 citations), Immunology (125 citations), Biotechnology (51 citations) and Genetics (58 citations). Larry Herrera has collaborated with scholars based in United States, Poland and Canada. Frequent co-authors include Eric Sandler, Ellen S. Vitetta, Roula Farah, George R. Buchanan, Victor Gheţie, Deborah B. Aquino, Victor M. Aquino, Birgitta Clinchy, E S Vitetta and Victor Aquino. Their work appears in journals such as Cancer, Leukemia, Cancer Research, Journal of Clinical Oncology and Critical Reviews in Eukaryotic Gene Expression.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.